Facebook Twitter LinkedIn Google Plus RSS

Merck partnering with S. Korean firm to develop biosimilars

By

Merck & Co., in the Whitehouse Station section of Readington, announced today an agreement with Samsung Bioepis Co. Ltd. to develop and commercialize several biosimilar candidates.

Under the agreement, Samsung Bioepis, of Seoul, South Korea, will be responsible for preclinical and clinical development, process development and manufacturing, clinical, trials and registration. Merck will be responsible for commercialization.

Samsung Bioepis will receive an upfront payment from Merck, product supply income and will be eligible for additional payments associated with certain clinical and regulatory milestones. Further financial terms were not disclosed.

 

Write to the Editorial Department at editorial@njbiz.com

Leave a Comment

test

Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy

Comments

close
Subscribe to Our Newsletters!
Click Here to Subscribe for Free Now!